Dexrapid 2 mg/ml solution for injection

Šalis: Airija

kalba: anglų

Šaltinis: HPRA (Health Products Regulatory Authority)

Nusipirk tai dabar

Parsisiųsti Prekės savybės (SPC)
24-03-2023
Parsisiųsti DSU (DSU)
06-06-2023

Veiklioji medžiaga:

Dexamethasone sodium phosphate

Prieinama:

VetViva Richter GmbH

ATC kodas:

QH02AB02

INN (Tarptautinis Pavadinimas):

Dexamethasone sodium phosphate

Vaisto forma:

Solution for injection

Recepto tipas:

POM: Prescription Only Medicine as defined in relevant national legislation

Gydymo sritis:

dexamethasone

Leidimo data:

2020-10-30

Prekės savybės

                                1
_[Version 8.1,01/2017] _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Dexrapid 2 mg/ml solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains
ACTIVE SUBSTANCE:
Dexamethasone
2.0 mg
(equivalent to 2.63 mg dexamethasone sodium phosphate)
EXCIPIENT:
Benzyl alcohol (E 1519) 15.6 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection
Clear and colourless to almost colourless solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses, cattle, pigs, dogs and cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Horses, cattle, pigs, dogs and cats:
Treatment of inflammatory or allergic conditions.
Horses:
Treatment of arthritis, bursitis or tenosynovitis.
Cattle
Induction of parturition.
Treatment of primary ketosis (acetonemia).
Dogs and cats
Short-term treatment of shock.
4.3
CONTRAINDICATIONS
Except in emergency situations, do not use in animals suffering from
diabetes mellitus, renal
insufficiency, cardiac insufficiency, hyperadrenocorticism, or
osteoporosis.
Do not use in viral infections during the viraemic stage or in cases
of systemic mycotic infections.
Do not use in animals suffering from gastrointestinal or corneal
ulcers, or demodicosis.
Do not administer intra-articularly where there is evidence of
fractures, bacterial joint infections and
aseptic bone necrosis.
Do not use in known cases of hypersensitivity to the active substance,
to corticosteroids and to any
other ingredient of the product.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
3
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Response to long-term therapy should be monitored at regular intervals
by a veterinary surgeon.
Use of corticosteroids in horses has been reported to induce
laminitis. Therefore, horses treated with
such preparations should be monitored frequently during the treatment
period.
Because of the pharmacological properties of the active ingredient,
special care should be taken when
t
                                
                                Perskaitykite visą dokumentą
                                
                            

Ieškokite perspėjimų, susijusių su šiuo produktu